Bioject Medical Technologies Inc. Reports Third Quarter 2011 Financial Results
Company to restructure operations after recent FDA communications
PORTLAND, Ore.--(BUSINESS WIRE)--Bioject Medical Technologies Inc. (OTCBB:BJCT), a leading developer of needle-free drug delivery systems, today reported financial results for the third quarter ended September 30, 2011.
“Unfortunately we have to report a mixed message. Third quarter 2011 revenue increased 107% over the same prior year-ago time period” Bioject reported revenues of $3.1 million for the quarter ended September 30, 2011, compared to revenues of $1.5 million in the comparable 2010 period. Product sales were $2.9 million in the 2011 period compared to $1.4 million in the comparable 2010 period. License and technology fees were $245,000 for the quarter ended September 30, 2011, compared to $91,000 in the comparable 2010 period.
PORTLAND, Ore.--(BUSINESS WIRE)--Bioject Medical Technologies Inc. (OTCBB:BJCT), a leading developer of needle-free drug delivery systems, today reported financial results for the third quarter ended September 30, 2011.
“Unfortunately we have to report a mixed message. Third quarter 2011 revenue increased 107% over the same prior year-ago time period” Bioject reported revenues of $3.1 million for the quarter ended September 30, 2011, compared to revenues of $1.5 million in the comparable 2010 period. Product sales were $2.9 million in the 2011 period compared to $1.4 million in the comparable 2010 period. License and technology fees were $245,000 for the quarter ended September 30, 2011, compared to $91,000 in the comparable 2010 period.